Open AccessRegorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways
Author(s) -
Divya Subramonian,
Nikki Phanhthilath,
Hannah Rinehardt,
Sean Flynn,
Yuchen Huo,
Jing Zhang,
Karen Messer,
Qianxing Mo,
Shixia Huang,
Jacqueline Lesperance,
Peter E. Zage
Publication year - 2020
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-020-0905-8
Subject(s) - regorafenib , cancer research , neuroblastoma , pi3k/akt/mtor pathway , protein kinase b , mapk/erk pathway , biology , pharmacology , kinase , medicine , signal transduction , microbiology and biotechnology , cell culture , cancer , colorectal cancer , genetics
Regorafenib is an inhibitor of multiple kinases with aberrant expression and activity in neuroblastoma tumours that have potential roles in neuroblastoma pathogenesis.